JOP20200045A1 - كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين - Google Patents

كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين

Info

Publication number
JOP20200045A1
JOP20200045A1 JOP/2020/0045A JOP20200045A JOP20200045A1 JO P20200045 A1 JOP20200045 A1 JO P20200045A1 JO P20200045 A JOP20200045 A JO P20200045A JO P20200045 A1 JOP20200045 A1 JO P20200045A1
Authority
JO
Jordan
Prior art keywords
adults
treatment
focal epilepsy
synthetic cbd
transdermal
Prior art date
Application number
JOP/2020/0045A
Other languages
English (en)
Inventor
Donna Gutterman
John Messenheimer
Terri Sebree
Ted Smith
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of JOP20200045A1 publication Critical patent/JOP20200045A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

غير متوفر
JOP/2020/0045A 2017-09-19 2018-09-18 كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين JOP20200045A1 (ar)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762560446P 2017-09-19 2017-09-19
US201762593575P 2017-12-01 2017-12-01
US201862613160P 2018-01-03 2018-01-03
US201862652995P 2018-04-05 2018-04-05
US201862660198P 2018-04-19 2018-04-19
PCT/IB2018/057189 WO2019058261A1 (en) 2017-09-19 2018-09-18 TRANSDERMAL SYNTHETIC CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS

Publications (1)

Publication Number Publication Date
JOP20200045A1 true JOP20200045A1 (ar) 2020-02-27

Family

ID=63762572

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0045A JOP20200045A1 (ar) 2017-09-19 2018-09-18 كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين

Country Status (11)

Country Link
US (4) US20190083388A1 (ar)
EP (1) EP3684411A1 (ar)
JP (2) JP2020534362A (ar)
KR (1) KR20200055067A (ar)
AU (1) AU2018337933A1 (ar)
BR (1) BR112020004947A2 (ar)
CA (1) CA3075719A1 (ar)
IL (2) IL301910A (ar)
JO (1) JOP20200045A1 (ar)
MX (2) MX2020003004A (ar)
WO (1) WO2019058261A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733156A1 (de) * 2019-05-02 2020-11-04 Gábor Fóti C.b.d.m therapie
EP4706647A3 (en) * 2019-09-17 2026-05-20 Harmony Biosciences Man Inc SYNGAP1 ENCEPHALOPATHY TREATMENT
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4037663A1 (en) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
MX2023006551A (es) * 2020-12-03 2023-08-17 Zynerba Pharmaceuticals Inc Tratamiento de las convulsiones refractarias.
CA3213953A1 (en) * 2021-04-08 2022-10-13 Fotios M. Plakogiannis Pharmaceutical composition and method for treating seizure disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
CA2772634C (en) * 2009-08-31 2017-11-21 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
JP2023171776A (ja) 2023-12-05
WO2019058261A9 (en) 2019-07-04
IL301910A (en) 2023-06-01
US20190083388A1 (en) 2019-03-21
MX2024002904A (es) 2024-04-04
US20250302734A1 (en) 2025-10-02
WO2019058261A1 (en) 2019-03-28
KR20200055067A (ko) 2020-05-20
BR112020004947A2 (pt) 2020-09-15
JP2020534362A (ja) 2020-11-26
MX2020003004A (es) 2020-11-06
EP3684411A1 (en) 2020-07-29
AU2018337933A1 (en) 2020-03-12
JP7650929B2 (ja) 2025-03-25
CA3075719A1 (en) 2019-03-28
US20210030665A1 (en) 2021-02-04
US20250213465A1 (en) 2025-07-03
IL272818A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CL2018002782A1 (es) Apósito modificado
IL263484A (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
CL2018000947S1 (es) Automóvil
IL272818A (en) Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
IL256166B (en) Compounds for use in treating neuromuscular disorders
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
PL3265053T3 (pl) Sposoby leczenia skóry
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
ECSP17015977A (es) Terapia de combinacion
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
BR112017009297A2 (pt) anticorpos antifator de complemento c1q humanizados e usos dos mesmos
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
HUE063044T2 (hu) Anti-CD38 ellenanyagok akut limfoblasztos leukémia kezelésére
IL247857B (en) Dynamic enablement of multithreading
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
CL2020000154A1 (es) Compuestos absorbentes
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
DK3331610T3 (da) Midler til anvendelse til behandling af gliom